HOOKIPA Pharma (HOOK)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	39.89 mm	39.89 mm	39.89 mm	39.89 mm	39.89 mm	39.89 mm
Cash burn (monthly)	6.69 mm	6.47 mm	8.35 mm	4.31 mm	6.98 mm	6.41 mm
Cash used (since last report)	15.41 mm	14.90 mm	19.24 mm	9.94 mm	16.08 mm	14.78 mm
Cash remaining	24.47 mm	24.98 mm	20.65 mm	29.95 mm	23.81 mm	25.11 mm
Runway (months of cash)	3.7	3.9	2.5	6.9	3.4	3.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

HOOK institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	23	44	-47.7%
Opened positions	8	7	+14.3%
Closed positions	29	13	+123.1%
Increased positions	1	16	-93.8%
Reduced positions	11	7	+57.1%

13F shares	Current	Prev Q	Change
Total value	5.63 bn	15.40 bn	-63.5%
Total shares	29.54 mm	64.50 mm	-54.2%
Total puts	0.00	46.60 k	EXIT
Total calls	0.00	98.50 k	EXIT
Total put/call ratio	–	0.5	–

Largest owners	Shares	Value	Change
GILD Gilead Sciences	18.76 mm	$10.60 mm	0.0%
Artal International S.C.A.	5.67 mm	$6.35 mm	0.0%
Sofinnova Capital Vi FCPR	3.14 mm	$4.05 mm	0.0%
Siren, L.L.C.	566.64 k	$2.44 bn	NEW
Invus Global Management	566.64 k	$3.58 mm	NEW
FMR	341.48 k	$1.47 bn	-90.0%
Vanguard	213.22 k	$916.85 mm	-89.9%
Acadian Asset Management	84.89 k	$364.00 k	-91.4%
Geode Capital Management	72.68 k	$312.60 mm	-89.7%
Dimensional Fund Advisors	48.64 k	$209.13 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Baker Bros. Advisors	0.00	-9.81 mm	EXIT
EcoR1 Capital	0.00	-5.72 mm	EXIT
Artal	0.00	-5.67 mm	EXIT
Knoll Capital Management	0.00	-5.52 mm	EXIT
FMR	341.48 k	-3.06 mm	-90.0%
Vanguard	213.22 k	-1.91 mm	-89.9%
Redmile	0.00	-1.06 mm	EXIT
Acadian Asset Management	84.89 k	-906.22 k	-91.4%
Geode Capital Management	72.68 k	-635.15 k	-89.7%
Siren, L.L.C.	566.64 k	+566.64 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

HOOK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
22 Jul 24	Malte Peters	Common Stock	Grant	Acquire A	No	No	0	108,695	0.00	108,695
22 Jul 24	Sean A Cassidy	Stock Option Common Stock	Grant	Acquire A	No	No	6.44	9,800	63.11 k	9,800
22 Jul 24	Mary Theresa Coelho	Common Stock	Grant	Acquire A	No	No	0	69,875	0.00	69,875
17 Jun 24	O'Neill Julie	Stock Option Common Stock	Grant	Acquire A	No	No	0.71	49,000	34.79 k	49,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Downgrades HOOKIPA Pharma to Neutral

10 Jan 25

HC Wainwright & Co. analyst Arthur He downgrades HOOKIPA Pharma (NASDAQ:HOOK) from Buy to Neutral.

Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City

3 Jan 25

Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal landscape.

RBC Capital Downgrades HOOKIPA Pharma to Sector Perform, Lowers Price Target to $2

20 Dec 24

RBC Capital analyst Brian Abrahams downgrades HOOKIPA Pharma (NASDAQ:HOOK) from Outperform to Sector Perform and lowers the price target from $48 to $2.

Press releases

From Benzinga Pro

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

7 Jan 25

NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for